ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration (FDA) approval of its Accent™ RF pacemaker and Anthem™ RF CRT-P (cardiac resynchronization therapy pacemaker). The company also announced FDA and European CE Mark approval of version 4.0 of the Merlin.net® Patient Care Network (PCN), which supports the Accent RF and Anthem RF devices.
